3M Biotech Co., Ltd

Based on technology,Create the future.

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsOral Anabolic Steroids

White Powder Oral Anabolic Steroids Tacrolimus CAS 104987-11-3 For Immunosuppressive

White Powder Oral Anabolic Steroids Tacrolimus CAS 104987-11-3 For Immunosuppressive

White Powder Oral Anabolic Steroids Tacrolimus CAS 104987-11-3 For Immunosuppressive

Product Details:

Place of Origin: China
Brand Name: Rund
Certification: ISO9001 , KOSHER , SGS
Model Number: CAS 104987-11-3

Payment & Shipping Terms:

Minimum Order Quantity: Negotiable
Price: Negotiable
Packaging Details: 10g/50g/100g/500g/1000g/foil bag, 25kg/drum
Delivery Time: Within 24h after confirming the payment
Payment Terms: T/T, Western Union, MoneyGram, BTCOIN
Supply Ability: 1000kg per month
Contact Now
Detailed Product Description
Name: Tacrolimus CAS: 104987-11-3
Appearance: White Powder Molecular Formula: C44H69NO12
MW: 804.02 Purity: 99%

Active Details Pharmaceutical Ingredients Tacrolimus CAS 104987-11-3 for Immunosuppressive,Treatment of eczema

 
Product name: Tacrolimus
Other Name: (2-propenyl)-,(3s-(3r*(e(1s*,3s*,4s*)),4s*,5r*,8s*,9e,12r*,14r*,15s*,16r*,18s*;,19s*,26ar*))-;16-dimethoxy-4,10,12,18-tetramethyl-8-3-(2-(4-hydroxy-3-methoxycyclohexyl)-1;19-epoxy-3h-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4h,23h)-tetrone,5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-(2-(4-hydroxy-3-methoxycyclohexyl)-14,16-dim;6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-5;fr900506;prograf;tsukubaenolide;
Original: China
CAS: 104987-11-3
Molecular formula: C44H69NO12
MW: 804.02
Leading time within 3 work days upon receipt of payment
Delivery Fast and secure shipping by EMS, DHL, TNT, FedEx, UPS
Purity 99%
Package Discreet and Hidden package according to specific requirement
Appearance White crystal powder
Certification SGS, ISO 9001, KOSHER
Minimum Order Quantity Negotiable
Price Negotiable
Molecular structure

 

CAS 104987-11-3 Active Pharmaceutical Ingredients Tacrolimus  for Immunosuppressive

 

 
Description
 

Tacrolimus is an immunosuppressive drug used mainly after allogeneic organ transplant to lower the risk of organ rejection. It achieves this by inhibiting the production of interleukin-2, a molecule that promotes the development and proliferation of T cells, which are vital to the body's learned (or adaptive) immune response.

 

Tacrolimus is also used in the treatment of other T cell-mediated diseases such as eczema (for which it is applied to the skin in a medicated ointment), severe refractory uveitis after bone marrow transplants, exacerbations of minimal change disease, Kimura's disease, and the skin condition vitiligo.

Chemically it is a 23-membered macrolide lactone that was first discovered in 1987 from the fermentation broth of a Japanese soil sample that contained the bacterium Streptomyces tsukubaensis.

 

Chemically it is a 23-membered macrolide lactone that was first discovered in 1987 from the fermentation broth of a Japanese soil sample that contained the bacterium Streptomyces tsukubaensis.

 
Applications
 
Immunosuppression following transplantation:
 
It has similar immunosuppressive properties to ciclosporin, but is much more potent. Immunosuppression with tacrolimus was associated with a significantly lower rate of acute rejection compared with ciclosporin-based immunosuppression (30.7% vs 46.4%) in one study. Clinical outcome is better with tacrolimus than with ciclosporin during the first year of liver transplantation. Long-term outcome has not been improved to the same extent. Tacrolimus is normally prescribed as part of a post-transplant cocktail including steroids, mycophenolate, and IL-2 receptor inhibitors such as basiliximab. Dosages are titrated to target blood levels.
 
Ulcerative colitis:
 
In recent years, tacrolimus has been used to suppress the inflammation associated with ulcerative colitis (UC), a form of inflammatory bowel disease. Although almost exclusively used in trial cases only, tacrolimus has shown to be significantly effective in the suppression of outbreaks of UC.
 
Dermatological use:
 

 

As an ointment, tacrolimus is used in the treatment of eczema, in particular atopic dermatitis. It suppresses inflammation in a similar way tosteroids, and is equally as effective as a mid-potency steroid. An important advantage of tacrolimus is that, unlike steroids, it does not cause skin thinning (atrophy), or other steroid related side effects.

It is applied on the active lesions until they heal off, but may also be used continuously in low doses (twice a week), and applied to the thinner skin over the face and eyelids. Clinical trials of up to one year have been conducted. Recently it has also been used to treat segmental vitiligo in children, especially in areas on the face.

 
Specification
 
COA:
 
Test Items Specification Results
Identification (IR) Should match with working standard Confirms
Melting point 246.0~252.0ºC 246.0ºC~248.0ºC
Water by KF Not more than 0.5% 0.14%
Loss on drying Not more than 0.5% 0.17%
Residue on ignition Not more than 0.2% 0.05%
Heavy Metals Not more than 20ppm Confirms
Single maximum impurity Not more than 0.5% 0.34%
Total impurities Not more than 1.0% 0.66%
Assay by HPLC 98.0% -102.0% 101.0%
 
 

Contact Details
3M Biotech Co., Ltd

Contact Person: Mr. Dr. Zhang

Send your inquiry directly to us (0 / 3000)